Product Information
- Dihydroprostaglandin E1Dihydro-pge1
- (11alpha,15S)-11,15-dihydroxy-9-oxoprostan-1-oic acid
- (11α,15S)-11,15-Dihydroxy-9-oxoprostan-1-oic acid
- (15S)-Dihydroprostaglandin E<sub>1</sub>
- 11,15-Dihydroxy-9-ketoprostanoic acid
- 11α,15-Dihydroxy-9-oxoprostanoic acid
- 13,14-Dihydro-PGE<sub>1</sub>
- 13,14-Dihydroprostaglandin E<sub>1</sub>
- 13,14-Dihydroprostaglandinee1
- 13,14-dihydro PGE1
- See more synonyms
- 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
- 9-Oxo-11Alpha,15S-Dihydroxy-Prostan-1-Oic Acid
- Cyclopentaneheptanoic acid, 3-hydroxy-2-(3-hydroxyoctyl)-5-oxo-, stereoisomer
- Dihydro-PGE<sub>1</sub>
- Dihydroprostaglandin E<sub>1</sub>
- PGE<sub>0</sub>
- Pge0
- Prostaglandin E<sub>0</sub>
- Prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11α,15S)-
- U 23307
- Dihydroprostaglandin E1
Prostaglandin E0 is a potent vasodilator that is synthesized by cyclooxygenase (COX) enzymes. It is used as a drug for the prevention of myocardial infarct, as well as for the treatment of chronic heart failure patients. Prostaglandin E0 also has clinical relevance in occlusive diseases such as angina pectoris, peripheral vascular disease, and Raynaud’s phenomenon. The prostaglandin receptor binding site in the human liver has been identified with hydroxyl group containing fatty acids. A two-way crossover study demonstrated the efficacy of prostaglandin E0 on muscle cell proliferation in an experimental model. Prostaglandin E0 can be used to regulate blood flow and reduce vascular resistance in patients with occlusive vascular disease, or who are at risk for thrombosis.
